Cas:103213-51-0 1,n6-ethenoadenosine-3′,5′-cyclic monophosphate sodium salt manufacturer & supplier

Chemical Name:1,n6-ethenoadenosine-3′,5′-cyclic monophosphate sodium salt

CAS.NO:103213-51-0

Synonyms:1,N6-Ethenoadenosine 3′:5′-cyclic monophosphate sodium salt;1,N6-Ethenoadenosine 3 inverted exclamation marka:5 inverted exclamation marka-cyclic monophosphate sodium salt

Molecular Formula:C₁₂H₁₁N₅NaO₆P

Molecular Weight:375.20900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:145.87000

Exact Mass:375.03400

LogP:0.29130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 1,N6-Ethenoadenosine 3′:5′-cyclic monophosphate sodium salt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,N6-Ethenoadenosine 3 inverted exclamation marka:5 inverted exclamation marka-cyclic monophosphate sodium salt physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,N6-Ethenoadenosine 3 inverted exclamation marka:5 inverted exclamation marka-cyclic monophosphate sodium salt Use and application,1,N6-Ethenoadenosine 3 inverted exclamation marka:5 inverted exclamation marka-cyclic monophosphate sodium salt technical grade,usp/ep/jp grade.

Related News: The StartScore model was developed by the company��s in-house supply chain experts based on actual performance data. 1,n6-ethenoadenosine-3′,5′-cyclic monophosphate sodium salt manufacturer The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun. 1,n6-ethenoadenosine-3′,5′-cyclic monophosphate sodium salt supplier The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 1,n6-ethenoadenosine-3′,5′-cyclic monophosphate sodium salt vendor The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 1,n6-ethenoadenosine-3′,5′-cyclic monophosphate sodium salt factory Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.